Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS9 | O00182 | 1/20 | 0.37 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.37 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.37 |
| ▸ | LGALS7; LGALS7B | P47929 | 1/20 | 0.37 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.35 |
| ▸ | ABCB1 | P08183 | 3/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | BCHE | P06276 | 1/20 | 0.33 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.33 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.32 |
| ▸ | SELP | P16109 | 3/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17590141 | 0.86 | LGALS9 (0.33) | LGALS9LGALS1LGALS3LGALS7; LGALS7BPTGES2 | |
| SCHEMBL4546317 | 0.86 | LGALS9 (0.33) | LGALS9LGALS1LGALS3LGALS7; LGALS7BPTGES2 | |
| SCHEMBL11981202 | 0.85 | USP2 (0.41) | LGALS9LGALS1LGALS3LGALS7; LGALS7BMEN1 | |
| SCHEMBL16812944 | 0.84 | LGALS9 (0.42) | LGALS9LGALS1LGALS3LGALS7; LGALS7BPTGES2 | |
| SCHEMBL12618618 | 0.84 | LGALS9 (0.42) | LGALS9LGALS1LGALS3LGALS7; LGALS7BPTGES2 | |
| SCHEMBL4546286 | 0.78 | — | — | |
| SCHEMBL16812938 | 0.77 | LGALS9 (0.43) | LGALS9LGALS1LGALS3LGALS7; LGALS7BPTGES2 | |
| SCHEMBL26823580 | 0.77 | LGALS9 (0.43) | LGALS9LGALS1LGALS3LGALS7; LGALS7BPTGES2 | |
| SCHEMBL16812935 | 0.77 | LGALS9 (0.43) | LGALS9LGALS1LGALS3LGALS7; LGALS7BPTGES2 | |
| SCHEMBL18385957 | 0.76 | LGALS9 (0.44) | LGALS9LGALS1LGALS3LGALS7; LGALS7BMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8987430-B2 | Efficient and scalable process for the manufacture of fondaparinux sodium | RELIABLE BIOPHARMACEUTICAL CORPORATION (US) | 2015-03-24 | — | — | US | disclosed |
| US-20130261291-A1 | EFFICIENT AND SCALABLE PROCESS FOR THE MANUFACTURE OF FONDAPARINUX SODIUM | RELIABLE BIOPHARMACEUTICAL CORPORATION (US) | 2013-10-03 | — | — | US | disclosed |
| US-8420790-B2 | Efficient and scalable process for the manufacture of Fondaparinux sodium | RELIABLE BIOPHARMACEUTICAL CORPORATION (US) | 2013-04-16 | — | — | US | disclosed |
| US-20120116066-A1 | EFFICIENT AND SCALABLE PROCESS FOR THE MANUFACTURE OF FONDAPARINUX SODIUM | RELIABLE BIOPHARMACEUTICAL CORPORATION (US) | 2012-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120116066-A1 | EFFICIENT AND SCALABLE PROCESS FOR THE MANUFACTURE OF FONDAPARINUX SODIUM | F11, F10, F2 | LGALS9 1981/4885LGALS1 2590/4885LGALS3 1861/4885 |
| US-20130261291-A1 | EFFICIENT AND SCALABLE PROCESS FOR THE MANUFACTURE OF FONDAPARINUX SODIUM | F11, F10, F2 | LGALS9 1981/4885LGALS1 2590/4885LGALS3 1861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.